---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Co-prescribed/Concomitant therapies. Topics: RAPIDe-3: concomitant long-term prophylaxis permitted, RAPIDe-3: long-term prophylaxis agents used by participants who treated at least one attack, RAPIDe-3: second capsule and conventional rescue medication rules, RAPIDe-1: long-term prophylaxis excluded and rescue medication rules, and 3 further topics. 7 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### RAPIDe-3: concomitant long-term prophylaxis permitted

> “Participants using concomitant hereditary angioedema long-term prophylaxis were also eligible.”
> “stratified by age (≥12 to <18 years or ≥18 years) and concomitant long-term prophylaxis use at the time of screening (yes or no).”
> “Of the 113 participants who treated at least one attack, 26 (23%) were receiving long-term prophylaxis at enrolment and during the study.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

> “Participants on long-term prophylactic therapy with plasma-derived C1-INH (danazol, anti-fibrinolytics, berotralstat, or lanadelumab) must be on a stable dose and regimen and intend to remain on the same dose for 6 months before screening and the duration of the study.”
> “Use of attenuated androgens for short-term prophylaxis within 2 weeks before screening.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

> “The patient population studied included adolescents and adults; participants on and not on long-term prophylaxis (LTP); people with HAE type 1, HAE type 2, and HAE with normal C1 inhibitor; and attacks studied included those of varying severities and across all body locations.”

Source: [Pharvaris RAPIDe-3 topline press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525305951/d69798dex991.htm)

<a id="topic-2.1.2.12-2"></a>

### RAPIDe-3: long-term prophylaxis agents used by participants who treated at least one attack

| Long-term prophylaxis | Deucrictibant (n=101) | Placebo (n=100) | Overall participants (n=113) |
| --- | --- | --- | --- |
| Any concomitant long-term prophylaxis | “20 (20%)” | “24 (24%)” | “26 (23%)” |
| Lanadelumab | “8 (8%)” | “10 (10%)” | “11 (10%)” |
| Berotralstat | “5 (5%)” | “7 (7%)” | “7 (6%)” |
| C1-esterase inhibitor | “4 (4%)” | “5 (5%)” | “5 (4%)” |
| Danazol | “3 (3%)” | “2 (2%)” | “3 (3%)” |

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.12-3"></a>

### RAPIDe-3: second capsule and conventional rescue medication rules

> “If symptoms persisted or progressed, a second capsule of the same study drug was permitted 4 h or later after the first capsule, and conventional on-demand therapy as rescue medication was permitted 1 h or more after the second capsule for non-laryngeal attacks. For laryngeal attacks, a second capsule of study drug was not permitted, and rescue medication was allowed at any time.”
> “An intercurrent event was defined as the use of rescue medication or selected prohibited medication after an attack was treated with study drug.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.12-4"></a>

### RAPIDe-1: long-term prophylaxis excluded and rescue medication rules

> “Patients receiving long-term prophylactic therapy for hereditary angioedema at screening were not eligible.”
> “Attacks with any symptoms involving the internal head or neck, including laryngeal attacks, or presenting with vomiting, did not qualify for study drug treatment and patients were instructed to immediately treat with standard on-demand medication.”
> “At 4 h or more after study drug administration, conventional on-demand therapy as rescue medication was allowed in case of insufficient symptom relief.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-2.1.2.12-5"></a>

### RAPIDe-2 Part B: concomitant long-term prophylaxis permitted

> “If a participant is receiving long-term prophylactic therapy with a medication indicated for HAE:, eg, plasma-derived C1INH, danazol at less than or equal to 200 mg/day, antifibrinolytics, berotralstat, or lanadelumab, they must be on a stable dose and regimen for at least 3 months before screening and intends to remain on the same dose for the duration of the study.”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-2.1.2.12-6"></a>

### Combined use of the immediate-release capsule during extended-release prophylaxis

> “The analysis demonstrated that combined use of a 40 mg deucrictibant XR tablet for prophylaxis and one or two deucrictibant IR 20 mg capsule(s), in the event of a breakthrough attack while on prophylaxis, is supported by evidence of adequate safety margins.”

Source: [Pharvaris EAACI 2026 press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/data-supporting-differentiated-profile-deucrictibant-hae)

> “The combined use of deucrictibant extended-release (XR) tablet 40 mg and immediate-release (IR) capsule(s) 20 mg in the event of a bradykinin-mediated angioedema attack occurring during prophylactic treatment with XR tablet is supported by adequate safety margins, subject to approval of each formulation by regulatory authorities.”
> “The evaluated scenarios (Table 1) included once daily deucrictibant XR tablet (40 mg, at steady state) combined with one deucrictibant IR capsule (20 mg), or two deucrictibant IR capsules taken 4 hours apart.”

Source: [Lesage et al. (2026b)](https://ir.pharvaris.com/static-files/67d704cc-422d-47b0-b130-9a6556fce46a)

<a id="topic-2.1.2.12-7"></a>

### CHAPTER-1: icatibant treatment of breakthrough attacks during deucrictibant prophylaxis

> “A recently published post-hoc analysis of the prophylaxis CHAPTER-1 study assessed the mean duration of breakthrough attacks, in both placebo and deucrictibant arms, that were treated with a single dose of icatibant, another bradykinin B2 receptor antagonist. The comparable mean total duration of icatibant-treated attacks in the placebo-icatibant and the deucrictibant-icatibant groups provide initial evidence on the efficacy of combining use of a bradykinin B2 receptor antagonist for prophylaxis and on-demand treatment of attacks.”

Source: [Pharvaris CIIC Spring 2026 press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/evidence-supporting-combined-use-deucrictibant-ir-deucrictibant)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
